<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33544228</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1590-3478</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title><ISOAbbreviation>Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>The links between diabetes mellitus and amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1377</StartPage><EndPage>1387</EndPage><MedlinePgn>1377-1387</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-021-05099-0</ELocationID><Abstract><AbstractText>ALS etiology and prognostic factors are mostly unknown. Metabolic diseases and especially diabetes mellitus (DM) have been variously related to ALS. However, pieces of evidence have been variegated and often conflicting so far. This review aims to give an overview of recent contributions focusing on the relationship between DM and ALS. DM seems to reduce the risk of developing ALS if diagnosed at a younger age; conversely, when diagnosed at an older age, DM seems protective against ALS. Such a relationship was not confirmed in Asian countries where DM increases the risk of ALS independently of the age of onset. Interestingly, DM does not affect ALS prognosis, possibly weakening the potential causal relationship between the two diseases. However, since most studies are observational, it is difficult to state the exact nature of such a relationship and several hypotheses have been made. A recent study using Mendelian randomization suggested that DM is indeed protective against ALS in the European population. However, these analyses are not without limits and further evidence is needed. DM is usually the core of a larger metabolic syndrome. Thus, other metabolic changes such as dyslipidemia, body mass index, and cardiovascular diseases should be collectively considered. Finally, hypermetabolism usually found in ALS patients should be considered too since all these metabolic changes could be compensation (or the cause) of the higher energy expenditure.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Vasta</LastName><ForeName>Rosario</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-0393-4736</Identifier><AffiliationInfo><Affiliation>ALS Center, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy. sarovasta@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>D'Ovidio</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>ALS Center, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Logroscino</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Clinical Research in Neurology, Center for Neurodegenerative Diseases and the Aging Brain, University of Bari "Aldo Moro", "Pia Fondazione Cardinale G. Panico", Tricase, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Center, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology 1, Azienda Ospedaliero Universitaria Citt&#xe0; della Salute e della Scienza, Turin, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Neurol Sci</MedlineTA><NlmUniqueID>100959175</NlmUniqueID><ISSNLinking>1590-1874</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Diabetes mellitus</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Metabolic syndrome</Keyword></KeywordList><CoiStatement>Rosario Vasta, Fabrizio d&#x2019;Ovidio: no disclosures. Giancarlo Logroscino is associated editor of the Neuroepidemiology journal (Karger, Basel). He has received support from: (1) Regione Puglia (DGR n. 1284 - 27.05.2015) for the project &#x201c;Registro Regionale per la SLA, la FTD-P e le patologie affini in Regione Puglia (SLAPDem register- www.slapdem.it) and from Italian Ministry of Health (Ricerca Corrente); (2) Regione Puglia and Consiglio Nazionale delle Ricerche (CNR) for Tecnomed Puglia for Precision Medicine D.G.R. n. 2117 of 21.11.2018. Adriano Chi&#xf2; serves on the editorial advisory board of Amyotrophic Lateral Sclerosis and Neurological Sciences and has received research support from the Italian Ministry of Health (Ricerca Finalizzata), Regione Piemonte (Ricerca Finalizzata), University of Turin, and the European Commission (Health Seventh Framework Programme), and serves on scientific advisory boards for Biogen Idec, Cytokinetics, and Avexis.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>5</Day><Hour>12</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33544228</ArticleId><ArticleId IdType="pmc">PMC7955983</ArticleId><ArticleId IdType="doi">10.1007/s10072-021-05099-0</ArticleId><ArticleId IdType="pii">10.1007/s10072-021-05099-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC. Amyotrophic lateral sclerosis. Lancet Lond Engl. 2011;377:942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingre C, Roos PM, Piehl F, et al. Risk factors for amyotrophic lateral sclerosis. Clin Epidemiol. 2015;7:181&#x2013;193. doi: 10.2147/CLEP.S37505.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S37505</ArticleId><ArticleId IdType="pmc">PMC4334292</ArticleId><ArticleId IdType="pubmed">25709501</ArticleId></ArticleIdList></Reference><Reference><Citation>(2013) Diagnosis and classification of diabetes mellitus. Diabetes Care 36:S67&#x2013;S74. 10.2337/dc13-S067</Citation></Reference><Reference><Citation>WHO | Global report on diabetes. In: WHO. http://www.who.int/diabetes/publications/grd-2016/en/. Accessed 16 Jan 2020</Citation></Reference><Reference><Citation>Dupuis L, Pradat P-F, Ludolph AC, Loeffler J-P. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:75&#x2013;82. doi: 10.1016/S1474-4422(10)70224-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70224-6</ArticleId><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito MD, da Silva GFG, Tilieri EM, Araujo BG, Cali&#xf3; ML, Rosenstock TR. Metabolic alteration and amyotrophic lateral sclerosis outcome: a systematic review. Front Neurol. 2019;10:1205. doi: 10.3389/fneur.2019.01205.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.01205</ArticleId><ArticleId IdType="pmc">PMC6879457</ArticleId><ArticleId IdType="pubmed">31824397</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell CS, Hollinger SK, Goswami SD, Polak MA, Lee RH, Glass JD. Antecedent disease is less prevalent in amyotrophic lateral sclerosis. Neurodegener Dis. 2015;15:109&#x2013;113. doi: 10.1159/000369812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000369812</ArticleId><ArticleId IdType="pmc">PMC4417009</ArticleId><ArticleId IdType="pubmed">25720304</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Kamel F, Bellocco R, Ye W, Fang F. Association between diabetes and amyotrophic lateral sclerosis in Sweden. Eur J Neurol. 2015;22:1436&#x2013;1442. doi: 10.1111/ene.12632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12632</ArticleId><ArticleId IdType="pmc">PMC4506907</ArticleId><ArticleId IdType="pubmed">25600257</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawada T. Type 2 diabetes and amyotrophic lateral sclerosis. Eur J Neurol. 2016;23:e9. doi: 10.1111/ene.12893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12893</ArticleId><ArticleId IdType="pubmed">26806221</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Fang F. Response to the letter &#x201c;Type 2 diabetes and amyotrophic lateral sclerosis.&#x201d;. Eur J Neurol. 2016;23:e26. doi: 10.1111/ene.12928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12928</ArticleId><ArticleId IdType="pubmed">27000982</ArticleId></ArticleIdList></Reference><Reference><Citation>Kioumourtzoglou M-A, Rotem RS, Seals RM, Gredal O, Hansen J, Weisskopf MG. Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. JAMA Neurol. 2015;72:905&#x2013;911. doi: 10.1001/jamaneurol.2015.0910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.0910</ArticleId><ArticleId IdType="pmc">PMC4975611</ArticleId><ArticleId IdType="pubmed">26030836</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Lu C-J, Chen R-C, Hou WH, Li CY. Risk of amyotrophic lateral sclerosis in patients with diabetes: a nationwide population-based cohort study. J Epidemiol. 2015;25:445&#x2013;451. doi: 10.2188/jea.JE20140176.</Citation><ArticleIdList><ArticleId IdType="doi">10.2188/jea.JE20140176</ArticleId><ArticleId IdType="pmc">PMC4444499</ArticleId><ArticleId IdType="pubmed">25947580</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai C-P, Lee JK-W, Lee CT-C. Type II diabetes mellitus and the incidence of amyotrophic lateral sclerosis. J Neurol. 2019;266:2233&#x2013;2243. doi: 10.1007/s00415-019-09405-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09405-x</ArticleId><ArticleId IdType="pubmed">31152300</ArticleId></ArticleIdList></Reference><Reference><Citation>Seelen M, van Doormaal PTC, Visser AE, Huisman MHB, Roozekrans MHJ, de Jong SW, van der Kooi AJ, de Visser M, Voermans NC, Veldink JH, van den Berg LH. Prior medical conditions and the risk of amyotrophic lateral sclerosis. J Neurol. 2014;261:1949&#x2013;1956. doi: 10.1007/s00415-014-7445-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-014-7445-1</ArticleId><ArticleId IdType="pubmed">25059395</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ovidio F, d&#x2019;Errico A, Carn&#xe0; P, et al. The role of pre-morbid diabetes on developing amyotrophic lateral sclerosis. Eur J Neurol. 2018;25:164&#x2013;170. doi: 10.1111/ene.13465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13465</ArticleId><ArticleId IdType="pubmed">28921834</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G. Motor neuron disease: are diabetes and amyotrophic lateral sclerosis related? Nat Rev Neurol. 2015;11:488&#x2013;490. doi: 10.1038/nrneurol.2015.145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.145</ArticleId><ArticleId IdType="pubmed">26281962</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Goldacre R, Ramagopalan S, Talbot K, Goldacre MJ. Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study. Neurology. 2013;81:1222&#x2013;1225. doi: 10.1212/WNL.0b013e3182a6cc13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182a6cc13</ArticleId><ArticleId IdType="pmc">PMC3795611</ArticleId><ArticleId IdType="pubmed">23946298</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A, Brown JA, Schulz PE. Diabetes mellitus in amyotrophic lateral sclerosis: Dr. Jekyll or Mr. Hyde? Eur J Neurol. 2015;22:1419&#x2013;1420. doi: 10.1111/ene.12660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12660</ArticleId><ArticleId IdType="pubmed">25597340</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;rner S, Kollewe K, Ilsemann J, M&#xfc;ller-Heine A, Dengler R, Krampfl K, Petri S. Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis. Eur J Neurol. 2013;20:647&#x2013;654. doi: 10.1111/ene.12015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12015</ArticleId><ArticleId IdType="pubmed">23094606</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Hyman T, Shui A, Allred P, Harms M, Liu J, Maragakis N, Schoenfeld D, Yu H, Atassi N, Cudkowicz M, Miller TM. Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis. Muscle Nerve. 2015;52:339&#x2013;343. doi: 10.1002/mus.24688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24688</ArticleId><ArticleId IdType="pmc">PMC4536144</ArticleId><ArticleId IdType="pubmed">25900666</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A, Schulz PE. Pre-morbid type 2 diabetes mellitus as a prognostic factor in amyotrophic lateral sclerosis. Muscle Nerve. 2015;52:690&#x2013;691. doi: 10.1002/mus.24758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24758</ArticleId><ArticleId IdType="pubmed">26137991</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Schoenfeld D, Shui A, Cudkowicz M, Miller TM. Reply: To. Muscle Nerve. 2015;52:691. doi: 10.1002/mus.24760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24760</ArticleId><ArticleId IdType="pubmed">26138218</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, Ferri L, Fasano A, Zucchi E, Fini N, Moglia C, Lunetta C, Marinou K, Ticozzi N, Drago Ferrante G, Scialo C, Sorar&#xf9; G, Trojsi F, Conte A, Falzone YM, Tortelli R, Russo M, Sansone VA, Mora G, Silani V, Volanti P, Caponnetto C, Querin G, Monsurr&#xf2; MR, Sabatelli M, Chi&#xf2; A, Riva N, Logroscino G, Messina S, Calvo A. Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis. Eur J Neurol. 2018;25:861&#x2013;868. doi: 10.1111/ene.13620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13620</ArticleId><ArticleId IdType="pubmed">29512869</ArticleId></ArticleIdList></Reference><Reference><Citation>Moglia C, Calvo A, Canosa A, Bertuzzo D, Cugnasco P, Solero L, Grassano M, Bersano E, Cammarosano S, Manera U, Parals. Pisano F, Mazzini L, Dalla Vecchia LA, Mora G, Chi&#xf2; A. Influence of arterial hypertension, type 2 diabetes and cardiovascular risk factors on ALS outcome: a population-based study. Amyotroph Lateral Scler Front Degener. 2017;18:590&#x2013;597. doi: 10.1080/21678421.2017.1336560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1336560</ArticleId><ArticleId IdType="pubmed">28616937</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q-Q, Chen Y, Cao B, Ou RW, Zhang L, Hou Y, Gao X, Shang H. Blood hemoglobin A1c levels and amyotrophic lateral sclerosis survival. Mol Neurodegener. 2017;12:69. doi: 10.1186/s13024-017-0211-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0211-y</ArticleId><ArticleId IdType="pmc">PMC5609007</ArticleId><ArticleId IdType="pubmed">28934974</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Chen L, Fan D (2019) The protective role of pre-morbid type 2 diabetes in patients with amyotrophic lateral sclerosis: a center-based survey in China. Amyotroph Lateral Scler Front Degener:1&#x2013;7. 10.1080/21678421.2019.1704010</Citation><ArticleIdList><ArticleId IdType="pubmed">31852260</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollinger SK, Okosun IS, Mitchell CS. Antecedent disease and amyotrophic lateral sclerosis: what is protecting whom? Front Neurol. 2016;7:47. doi: 10.3389/fneur.2016.00047.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2016.00047</ArticleId><ArticleId IdType="pmc">PMC4810157</ArticleId><ArticleId IdType="pubmed">27065942</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng P, Wang T, Zheng J, Zhou X. Causal association of type 2 diabetes with amyotrophic lateral sclerosis: new evidence from Mendelian randomization using GWAS summary statistics. BMC Med. 2019;17:225. doi: 10.1186/s12916-019-1448-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-019-1448-9</ArticleId><ArticleId IdType="pmc">PMC6892209</ArticleId><ArticleId IdType="pubmed">31796040</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim MA, Bence KK, Sandesara I, Andreux P, Auwerx J, Ishibashi J, Seale P, Kalb RG. Genetically altering organismal metabolism by leptin-deficiency benefits a mouse model of amyotrophic lateral sclerosis. Hum Mol Genet. 2014;23:4995&#x2013;5008. doi: 10.1093/hmg/ddu214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu214</ArticleId><ArticleId IdType="pmc">PMC4140473</ArticleId><ArticleId IdType="pubmed">24833719</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghero G, Pugliatti M, Marrosu F, et al. TBK1 is associated with ALS and ALS-FTD in Sardinian patients. Neurobiol Aging. 2016;43:180.e1&#x2013;180.e5. doi: 10.1016/j.neurobiolaging.2016.03.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.03.028</ArticleId><ArticleId IdType="pubmed">27156075</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbohm A, Nagel G, Peter RS, Brehme T, Koenig W, Dupuis L, Rothenbacher D, Ludolph AC, for the ALS Registry Study Group Association of serum retinol-binding protein 4 concentration with risk for and prognosis of amyotrophic lateral sclerosis. JAMA Neurol. 2018;75:600&#x2013;607. doi: 10.1001/jamaneurol.2017.5129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.5129</ArticleId><ArticleId IdType="pmc">PMC5885207</ArticleId><ArticleId IdType="pubmed">29482216</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaronen M, Goldsteins G, Koistinaho J. ER stress and unfolded protein response in amyotrophic lateral sclerosis-a controversial role of protein disulphide isomerase. Front Cell Neurosci. 2014;8:402. doi: 10.3389/fncel.2014.00402.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00402</ArticleId><ArticleId IdType="pmc">PMC4251436</ArticleId><ArticleId IdType="pubmed">25520620</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekura K, Suzuki H, Aiso S, Matsuoka M. ER stress and unfolded protein response in amyotrophic lateral sclerosis. Mol Neurobiol. 2009;39:81&#x2013;89. doi: 10.1007/s12035-009-8054-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-009-8054-3</ArticleId><ArticleId IdType="pubmed">19184563</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Park KS, Kim SH, Yu J, Zhao K, Yu L, Oh KW, Lee K, Kim J, Chaggar K, Li Y, Dolphin AC, Catterall WA, Ryu SH, Yang SN, Berggren PO. IgGs from patients with amyotrophic lateral sclerosis and diabetes target CaV&#x3b1;2&#x3b4;1 subunits impairing islet cell function and survival. Proc Natl Acad Sci U S A. 2019;116:26816&#x2013;26822. doi: 10.1073/pnas.1911956116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1911956116</ArticleId><ArticleId IdType="pmc">PMC6936400</ArticleId><ArticleId IdType="pubmed">31826954</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki K, Araki A, Honda D, Izumoto T, Hashizume A, Hijikata Y, Yamada S, Iguchi Y, Hara A, Ikumi K, Kawai K, Ishigaki S, Nakamichi Y, Tsunekawa S, Seino Y, Yamamoto A, Takayama Y, Hidaka S, Tominaga M, Ohara-Imaizumi M, Suzuki A, Ishiguro H, Enomoto A, Yoshida M, Arima H, Muramatsu SI, Sobue G, Katsuno M. TDP-43 regulates early-phase insulin secretion via CaV1.2-mediated exocytosis in islets. J Clin Invest. 2019;130:3578&#x2013;3593. doi: 10.1172/JCI124481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI124481</ArticleId><ArticleId IdType="pmc">PMC6715357</ArticleId><ArticleId IdType="pubmed">31355778</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A, Abid A, Schulz PE. Diabetes mellitus and amyotrophic lateral sclerosis: time to bridge the gap between the bench and the bedside. Eur J Neurol. 2018;25:3&#x2013;4. doi: 10.1111/ene.13481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13481</ArticleId><ArticleId IdType="pubmed">29044904</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneb HM, Sharp PS, Rahmani-Kondori N, Wells DJ. Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice. PLoS One. 2011;6:e24189. doi: 10.1371/journal.pone.0024189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0024189</ArticleId><ArticleId IdType="pmc">PMC3164704</ArticleId><ArticleId IdType="pubmed">21909419</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlan KS, Mitchem MR, Hogg MC, Prehn JHM. &#x201c;Preconditioning&#x201d; with latrepirdine, an adenosine 5&#x2019;-monophosphate-activated protein kinase activator, delays amyotrophic lateral sclerosis progression in SOD1(G93A) mice. Neurobiol Aging. 2015;36:1140&#x2013;1150. doi: 10.1016/j.neurobiolaging.2014.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.09.022</ArticleId><ArticleId IdType="pubmed">25443289</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto K, Kihira T, Kondo T, Kobashi G, Washio M, Sasaki S, Yokoyama T, Miyake Y, Sakamoto N, Inaba Y, Nagai M. Nutritional status and risk of amyotrophic lateral sclerosis in Japan. Amyotroph Lateral Scler Off Publ World Fed Neurol Res Group Mot Neuron Dis. 2007;8:300&#x2013;304. doi: 10.1080/17482960701472249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701472249</ArticleId><ArticleId IdType="pubmed">17852010</ArticleId></ArticleIdList></Reference><Reference><Citation>Wills A-M, Hubbard J, Macklin EA, Glass J, Tandan R, Simpson EP, Brooks B, Gelinas D, Mitsumoto H, Mozaffar T, Hanes GP, Ladha SS, Heiman-Patterson T, Katz J, Lou JS, Mahoney K, Grasso D, Lawson R, Yu H, Cudkowicz M, MDA Clinical Research Network Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Lond Engl. 2014;383:2065&#x2013;2072. doi: 10.1016/S0140-6736(14)60222-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)60222-1</ArticleId><ArticleId IdType="pmc">PMC4176708</ArticleId><ArticleId IdType="pubmed">24582471</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A, Salamone AR, Strutt AM, Murthy SB, Wheaton M, McDowell EJ, Simpson E, Appel SH, York MK, Schulz PE. ALS disease onset may occur later in patients with pre-morbid diabetes mellitus. Eur J Neurol. 2010;17:733&#x2013;739. doi: 10.1111/j.1468-1331.2009.02923.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02923.x</ArticleId><ArticleId IdType="pubmed">20074230</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali O. Genetics of type 2 diabetes. World J Diabetes. 2013;4:114&#x2013;123. doi: 10.4239/wjd.v4.i4.114.</Citation><ArticleIdList><ArticleId IdType="doi">10.4239/wjd.v4.i4.114</ArticleId><ArticleId IdType="pmc">PMC3746083</ArticleId><ArticleId IdType="pubmed">23961321</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, Chi&#xf2; A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 2018;17:94&#x2013;102. doi: 10.1016/S1474-4422(17)30401-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30401-5</ArticleId><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Auburger G, Gispert S, Lahut S, Om&#xfc;r O, Damrath E, Heck M, Ba&#x15f;ak N. 12q24 locus association with type 1 diabetes: SH2B3 or ATXN2? World J Diabetes. 2014;5:316&#x2013;327. doi: 10.4239/wjd.v5.i3.316.</Citation><ArticleIdList><ArticleId IdType="doi">10.4239/wjd.v5.i3.316</ArticleId><ArticleId IdType="pmc">PMC4058736</ArticleId><ArticleId IdType="pubmed">24936253</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, Kim H-J, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, Padmanabhan A, Clay-Falcone D, McCluskey L, Elman L, Juhr D, Gruber PJ, R&#xfc;b U, Auburger G, Trojanowski JQ, Lee VMY, van Deerlin VM, Bonini NM, Gitler AD. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075. doi: 10.1038/nature09320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09320</ArticleId><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahut S, &#xd6;m&#xfc;r &#xd6;, Uyan &#xd6;, A&#x11f;&#x131;m ZS, &#xd6;zo&#x11f;uz A, Parman Y, Deymeer F, Oflazer P, Ko&#xe7; F, &#xd6;z&#xe7;elik H, Auburger G, Ba&#x15f;ak AN. ATXN2 and its neighbouring gene SH2B3 are associated with increased ALS risk in the Turkish population. PLoS One. 2012;7:e42956. doi: 10.1371/journal.pone.0042956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0042956</ArticleId><ArticleId IdType="pmc">PMC3423429</ArticleId><ArticleId IdType="pubmed">22916186</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouteloup C, Desport J-C, Clavelou P, Guy N, Derumeaux-Burel H, Ferrier A, Couratier P. Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol. 2009;256:1236&#x2013;1242. doi: 10.1007/s00415-009-5100-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-5100-z</ArticleId><ArticleId IdType="pubmed">19306035</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Oudart H, Ren&#xe9; F, et al. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci U S A. 2004;101:11159&#x2013;11164. doi: 10.1073/pnas.0402026101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0402026101</ArticleId><ArticleId IdType="pmc">PMC503756</ArticleId><ArticleId IdType="pubmed">15263088</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu H, Deng H, Hu Z. Plasma progranulin concentrations are increased in patients with type 2 diabetes and obesity and correlated with insulin resistance. Mediat Inflamm. 2013;2013:360190&#x2013;360196. doi: 10.1155/2013/360190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/360190</ArticleId><ArticleId IdType="pmc">PMC3588183</ArticleId><ArticleId IdType="pubmed">23476101</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird AS, Van Hoecke A, De Muynck L, et al. Progranulin is neurotrophic in vivo and protects against a mutant TDP-43 induced axonopathy. PLoS One. 2010;5:e13368. doi: 10.1371/journal.pone.0013368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0013368</ArticleId><ArticleId IdType="pmc">PMC2954192</ArticleId><ArticleId IdType="pubmed">20967127</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu&#xf1;oz MC, Giani JF, Mayer MA, Toblli JE, Turyn D, Dominici FP. TANK-binding kinase 1 mediates phosphorylation of insulin receptor at serine residue 994: a potential link between inflammation and insulin resistance. J Endocrinol. 2009;201:185&#x2013;197. doi: 10.1677/JOE-08-0276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1677/JOE-08-0276</ArticleId><ArticleId IdType="pubmed">19251743</ArticleId></ArticleIdList></Reference><Reference><Citation>Joardar A, Manzo E, Zarnescu DC. Metabolic dysregulation in amyotrophic lateral sclerosis: challenges and opportunities. Curr Genet Med Rep. 2017;5:108&#x2013;114. doi: 10.1007/s40142-017-0123-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40142-017-0123-8</ArticleId><ArticleId IdType="pmc">PMC5647833</ArticleId><ArticleId IdType="pubmed">29057168</ArticleId></ArticleIdList></Reference><Reference><Citation>Riancho J, Berciano MT, Ruiz-Soto M, Berciano J, Landreth G, Lafarga M. Retinoids and motor neuron disease: potential role in amyotrophic lateral sclerosis. J Neurol Sci. 2016;360:115&#x2013;120. doi: 10.1016/j.jns.2015.11.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.11.058</ArticleId><ArticleId IdType="pmc">PMC6558957</ArticleId><ArticleId IdType="pubmed">26723986</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauskolb S, Dombert B, Sendtner M. Insulin-like growth factor 1 in diabetic neuropathy and amyotrophic lateral sclerosis. Neurobiol Dis. 2017;97:103&#x2013;113. doi: 10.1016/j.nbd.2016.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.04.007</ArticleId><ArticleId IdType="pubmed">27142684</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulware SD, Tamborlane WV, Rennert NJ, Gesundheit N, Sherwin RS. Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults. J Clin Invest. 1994;93:1131&#x2013;1139. doi: 10.1172/JCI117065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI117065</ArticleId><ArticleId IdType="pmc">PMC294058</ArticleId><ArticleId IdType="pubmed">8132753</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedrich N, Thuesen B, J&#xf8;rgensen T, et al. The association between IGF-I and insulin resistance: a general population study in Danish adults. Diabetes Care. 2012;35:768&#x2013;773. doi: 10.2337/dc11-1833.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc11-1833</ArticleId><ArticleId IdType="pmc">PMC3308317</ArticleId><ArticleId IdType="pubmed">22374641</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilic E, Bilic E, Rudan I, Kusec V, Zurak N, Delimar D, Zagar M. Comparison of the growth hormone, IGF-1 and insulin in cerebrospinal fluid and serum between patients with motor neuron disease and healthy controls. Eur J Neurol. 2006;13:1340&#x2013;1345. doi: 10.1111/j.1468-1331.2006.01503.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2006.01503.x</ArticleId><ArticleId IdType="pubmed">17116217</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, Murphy MF, Natter HM, Norris FH, Rudnicki SA, The North America ALS/IGF-I Study Group* Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology. 1997;49:1621&#x2013;1630. doi: 10.1212/wnl.49.6.1621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.49.6.1621</ArticleId><ArticleId IdType="pubmed">9409357</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, Barkhaus PE, Bosch P, Boylan K, David WS, Feldman E, Glass J, Gutmann L, Katz J, King W, Luciano CA, McCluskey LF, Nash S, Newman DS, Pascuzzi RM, Pioro E, Sams LJ, Scelsa S, Simpson EP, Subramony SH, Tiryaki E, Thornton CA. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology. 2008;71:1770&#x2013;1775. doi: 10.1212/01.wnl.0000335970.78664.36.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000335970.78664.36</ArticleId><ArticleId IdType="pmc">PMC2617770</ArticleId><ArticleId IdType="pubmed">19029516</ArticleId></ArticleIdList></Reference><Reference><Citation>Borasio GD, Robberecht W, Leigh PN, Emile J, Guiloff RJ, Jerusalem F, Silani V, Vos PE, Wokke JHJ, Dobbins T, European ALS/IGF-I Study Group* A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology. 1998;51:583&#x2013;586. doi: 10.1212/wnl.51.2.583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.51.2.583</ArticleId><ArticleId IdType="pubmed">9710040</ArticleId></ArticleIdList></Reference><Reference><Citation>Beauverd M, Mitchell JD, Wokke JHJ, Borasio GD. Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2012;11:CD002064. doi: 10.1002/14651858.CD002064.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD002064.pub3</ArticleId><ArticleId IdType="pubmed">23152212</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano R, Reed JC. ER stress-induced cell death mechanisms. Biochim Biophys Acta. 2013;1833:3460&#x2013;3470. doi: 10.1016/j.bbamcr.2013.06.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2013.06.028</ArticleId><ArticleId IdType="pmc">PMC3834229</ArticleId><ArticleId IdType="pubmed">23850759</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer RM, Mayer B, Kuncl RW et al (2019) Identifying potential targets for prevention and treatment of amyotrophic lateral sclerosis based on a screen of Medicare prescription drugs. Amyotroph Lateral Scler Front Degener:1&#x2013;11. 10.1080/21678421.2019.1682613</Citation><ArticleIdList><ArticleId IdType="pubmed">31684770</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker VM, Davies NM, Jones T, Kehoe PG, Martin RM. Can commonly prescribed drugs be repurposed for the prevention or treatment of Alzheimer&#x2019;s and other neurodegenerative diseases? Protocol for an observational cohort study in the UK Clinical Practice Research Datalink. BMJ Open. 2016;6:e012044. doi: 10.1136/bmjopen-2016-012044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-012044</ArticleId><ArticleId IdType="pmc">PMC5168636</ArticleId><ArticleId IdType="pubmed">27965247</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Dengler R, Heneka MT, Meyer T, Zierz S, Kassubek J, Fischer W, Steiner F, Lindauer E, Otto M, Dreyhaupt J, Grehl T, Hermann A, Winkler AS, Bogdahn U, Benecke R, Schrank B, Wessig C, Grosskreutz J, Ludolph AC, the GERP ALS Study Group A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One. 2012;7:e37885. doi: 10.1371/journal.pone.0037885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0037885</ArticleId><ArticleId IdType="pmc">PMC3371007</ArticleId><ArticleId IdType="pubmed">22715372</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018;19:121&#x2013;135. doi: 10.1038/nrm.2017.95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm.2017.95</ArticleId><ArticleId IdType="pmc">PMC5780224</ArticleId><ArticleId IdType="pubmed">28974774</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y-J, Chern Y. AMPK-mediated regulation of neuronal metabolism and function in brain diseases. J Neurogenet. 2015;29:50&#x2013;58. doi: 10.3109/01677063.2015.1067203.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/01677063.2015.1067203</ArticleId><ArticleId IdType="pubmed">26119401</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Sui Y, Gao W, Cai B, Fan D. Effects of diet on adenosine monophosphate-activated protein kinase activity and disease progression in an amyotrophic lateral sclerosis model. J Int Med Res. 2015;43:67&#x2013;79. doi: 10.1177/0300060514554725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0300060514554725</ArticleId><ArticleId IdType="pubmed">25534414</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y-J, Ju T-C, Chen H-M, Jang YS, Lee LM, Lai HL, Tai HC, Fang JM, Lin YL, Tu PH, Chern Y. Activation of AMP-activated protein kinase &#x3b1;1 mediates mislocalization of TDP-43 in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2015;24:787&#x2013;801. doi: 10.1093/hmg/ddu497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu497</ArticleId><ArticleId IdType="pubmed">25256353</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y-J, Lee L-M, Lai H-L, Chern Y. Aberrant activation of AMP-activated protein kinase contributes to the abnormal distribution of HuR in amyotrophic lateral sclerosis. FEBS Lett. 2015;589:432&#x2013;439. doi: 10.1016/j.febslet.2014.12.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2014.12.029</ArticleId><ArticleId IdType="pubmed">25592834</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Lange DJ, Voustianiouk A, MacGrogan D, Ho L, Suh J, Humala N, Thiyagarajan M, Wang J, Pasinetti GM. A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neurosci. 2006;7:29. doi: 10.1186/1471-2202-7-29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-7-29</ArticleId><ArticleId IdType="pmc">PMC1488864</ArticleId><ArticleId IdType="pubmed">16584562</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinetti GM, Bilski AE, Zhao W. Sirtuins as therapeutic targets of ALS. Cell Res. 2013;23:1073&#x2013;1074. doi: 10.1038/cr.2013.94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2013.94</ArticleId><ArticleId IdType="pmc">PMC3760621</ArticleId><ArticleId IdType="pubmed">23856645</ArticleId></ArticleIdList></Reference><Reference><Citation>Herskovits AZ, Guarente L. Sirtuin deacetylases in neurodegenerative diseases of aging. Cell Res. 2013;23:746&#x2013;758. doi: 10.1038/cr.2013.70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2013.70</ArticleId><ArticleId IdType="pmc">PMC3674397</ArticleId><ArticleId IdType="pubmed">23689277</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W, Song Y, Kincaid B, Bossy B, Bossy-Wetzel E. Mutant SOD1G93A triggers mitochondrial fragmentation in spinal cord motor neurons: neuroprotection by SIRT3 and PGC-1&#x3b1;. Neurobiol Dis. 2013;51:72&#x2013;81. doi: 10.1016/j.nbd.2012.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.07.004</ArticleId><ArticleId IdType="pmc">PMC3992938</ArticleId><ArticleId IdType="pubmed">22819776</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandres-Ciga S, Noyce AJ, Traynor BJ. Mendelian randomization-a journey from obscurity to center stage with a few potholes along the way. JAMA Neurol. 2019;77:7&#x2013;8. doi: 10.1001/jamaneurol.2019.3419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.3419</ArticleId><ArticleId IdType="pubmed">31609383</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckel RH, Alberti KGMM, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet Lond Engl. 2010;375:181&#x2013;183. doi: 10.1016/S0140-6736(09)61794-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)61794-3</ArticleId><ArticleId IdType="pubmed">20109902</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray N, Picone G, Sloan F, Yashkin A. The relationship between BMI and onset of diabetes mellitus and its complications. South Med J. 2015;108:29&#x2013;36. doi: 10.14423/SMJ.0000000000000214.</Citation><ArticleIdList><ArticleId IdType="doi">10.14423/SMJ.0000000000000214</ArticleId><ArticleId IdType="pmc">PMC4457375</ArticleId><ArticleId IdType="pubmed">25580754</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Deng J, Jaffa M, Cudkowicz ME, Wills AM. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve. 2011;44:20&#x2013;24. doi: 10.1002/mus.22114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.22114</ArticleId><ArticleId IdType="pmc">PMC4441750</ArticleId><ArticleId IdType="pubmed">21607987</ArticleId></ArticleIdList></Reference><Reference><Citation>Moglia C, Calvo A, Grassano M, Canosa A, Manera U, D'Ovidio F, Bombaci A, Bersano E, Mazzini L, Mora G, Chi&#xf2; A. Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort. J Neurol Neurosurg Psychiatry. 2019;90:666&#x2013;673. doi: 10.1136/jnnp-2018-319611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319611</ArticleId><ArticleId IdType="pubmed">30630957</ArticleId></ArticleIdList></Reference><Reference><Citation>Dokken BB. The pathophysiology of cardiovascular disease and diabetes: beyond blood pressure and lipids. Diabetes Spectr. 2008;21:160&#x2013;165. doi: 10.2337/diaspect.21.3.160.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diaspect.21.3.160</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Ilardi A, et al. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology. 2009;73:1681&#x2013;1685. doi: 10.1212/WNL.0b013e3181c1df1e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181c1df1e</ArticleId><ArticleId IdType="pubmed">19917991</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A, Moglia C, Lunetta C, Marinou K, Ticozzi N, Ferrante GD, Scialo C, Sorar&#xf9; G, Trojsi F, Conte A, Falzone YM, Tortelli R, Russo M, Chi&#xf2; A, Sansone VA, Mora G, Silani V, Volanti P, Caponnetto C, Querin G, Monsurr&#xf2; MR, Sabatelli M, Riva N, Logroscino G, Messina S, Fini N, Mandrioli J. Factors predicting survival in ALS: a multicenter Italian study. J Neurol. 2017;264:54&#x2013;63. doi: 10.1007/s00415-016-8313-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-016-8313-y</ArticleId><ArticleId IdType="pubmed">27778156</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandres-Ciga S, Noyce AJ, Hemani G, Nicolas A, Calvo A, Mora G, The ITALSGEN Consortium. Arosio A, Barberis M, Bartolomei I, Battistini S, Benigni M, Borghero G, Brunetti M, Calvo A, Cammarosano S, Cannas A, Canosa A, Capasso M, Caponnetto C, Caredda C, Carrera P, Casale F, Cavallaro S, Chi&#xf2; A, Colletti T, Conforti FL, Conte A, Corrado L, Costantino E, D'Alfonso S, Fasano A, Femiano C, Ferrarese C, Fini N, Floris G, Fuda G, Giannini F, Grassano M, Ilardi A, la Bella V, Lattante S, Logroscino G, Logullo FO, Loi D, Lunetta C, Mancardi G, Mandich P, Mandrioli J, Manera U, Marangi G, Marinou K, Marrali G, Marrosu MG, Mazzini L, Melis M, Messina S, Moglia C, Monsurro MR, Mora G, Mosca L, Occhineri P, Origone P, Pani C, Penco S, Petrucci A, Piccirillo G, Pirisi A, Pisano F, Pugliatti M, Restagno G, Ricci C, Rita Murru M, Riva N, Sabatelli M, Salvi F, Santarelli M, Sideri R, Simone I, Spataro R, Tanel R, Tedeschi G, Tranquilli S, Tremolizzo L, Trojsi F, Volanti P, Zollino M, The International ALS Genomics Consortium. Abramzon Y, Arepalli S, Baloh RH, Bowser R, Brady CB, Brice A, Broach J, Campbell RH, Camu W, Chia R, Chi&#xf2; A, Cooper-Knock J, Cusi D, Ding J, Drepper C, Drory VE, Dunckley TL, Eicher JD, Faghri F, Feldman E, Kay Floeter M, Fratta P, Geiger JT, Gerhard G, Gibbs JR, Gibson SB, Glass JD, Hardy J, Harms MB, Heiman-Patterson TD, Hernandez DG, Jansson L, Kamel F, Kirby J, Kowall NW, Laaksovirta H, Landi F, le Ber I, Lumbroso S, MacGowan DJL, Maragakis NJ, Mouzat K, Murphy NA, Myllykangas L, Nalls MA, Nicolas A, Orrell RW, Ostrow LW, Pamphlett R, Pickering-Brown S, Pioro E, Pliner HA, Pulst SM, Ravits JM, Renton AE, Rivera A, Robbrecht W, Rogaeva E, Rollinson S, Rothstein JD, Salvi E, Scholz SW, Sendtner M, Shaw PJ, Sidle KC, Simmons Z, Singleton AB, Stone DC, Sulkava R, Tienari PJ, Traynor BJ, Trojanowski JQ, Troncoso JC, van Damme P, van Deerlin VM, van den Bosch L, Zinman L, Tienari PJ, Stone DJ, Nalls MA, Singleton AB, Chi&#xf2; A, Traynor BJ. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol. 2019;85:470&#x2013;481. doi: 10.1002/ana.25431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25431</ArticleId><ArticleId IdType="pmc">PMC6450729</ArticleId><ArticleId IdType="pubmed">30723964</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed RM, Dupuis L, Kiernan MC. Paradox of amyotrophic lateral sclerosis and energy metabolism. J Neurol Neurosurg Psychiatry. 2018;89:1013&#x2013;1014. doi: 10.1136/jnnp-2018-318428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318428</ArticleId><ArticleId IdType="pubmed">29735514</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>